79 related articles for article (PubMed ID: 33403012)
1. Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Liang J; Gu W; Jin J; Zhang H; Chen Z; Tang Y; Zhang S; Yang S; Deng Y; Feng W
Ther Adv Med Oncol; 2020; 12():1758835920968472. PubMed ID: 33403012
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer.
Li N; Bai C; Zhang R; Ma L; Ren X; Zhang J; Fu Z; Zhao L
Transl Oncol; 2021 Feb; 14(2):101004. PubMed ID: 33383486
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer.
Zhou T; Wu C; Zhang C; Li P; Dong H; Zhou X; Lu H; Qi C; Ling Y
J Thorac Dis; 2019 May; 11(5):1831-1837. PubMed ID: 31285875
[TBL] [Abstract][Full Text] [Related]
4. Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
Zhu Y; Lin Z; Wu C
Evid Based Complement Alternat Med; 2023; 2023():4242346. PubMed ID: 37089715
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis.
Qin S; Han X; Li Z
Oncol Lett; 2024 Jan; 27(1):25. PubMed ID: 38073772
[TBL] [Abstract][Full Text] [Related]
6. A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Huang H; Zhang H; Cao B
Thorac Cancer; 2024 Feb; 15(5):427-433. PubMed ID: 38211967
[TBL] [Abstract][Full Text] [Related]
7. The efficacy, safety, and beneficiary population of angiogenesis inhibitor apatinib plus chemotherapy in recurrent platinum-resistant ovarian cancer patients: A comparative cohort study.
Wu C; Yan J; Wu Y
J Obstet Gynaecol Res; 2024 Jun; ():. PubMed ID: 38839575
[TBL] [Abstract][Full Text] [Related]
8. Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment.
Chen S; Sun J; Zhao L; Sun Y; Jia D; Song Y; Luo J; Lei H; Liu N
Exp Ther Med; 2021 Jan; 21(1):62. PubMed ID: 33365062
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines.
Gu J; Ni X; Ji J; Wei G; Shi L; Xu C
Evid Based Complement Alternat Med; 2022; 2022():8060026. PubMed ID: 35529932
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17.
Chen R; Chen QT; Dong YH
Oncol Lett; 2019 Jun; 17(6):5447-5452. PubMed ID: 31186764
[TBL] [Abstract][Full Text] [Related]
11. Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report.
Cheng L; Jiao Q; Jin Y; Fu H; Zhang H; Chen L
Onco Targets Ther; 2019; 12():10495-10500. PubMed ID: 31819530
[TBL] [Abstract][Full Text] [Related]
12. Retracted: Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9821932. PubMed ID: 38093893
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma.
Gu H; Li J; You N; Wu K; Wang Z; Wang L; Zhu Y; Liu Q; Peng X; Zheng L
Ann Transl Med; 2020 Dec; 8(24):1677. PubMed ID: 33490189
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
15. Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report.
Li XX
Am J Ther; 2021 Jul; 29(2):e269-e271. PubMed ID: 33416243
[No Abstract] [Full Text] [Related]
16. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer.
Zhao L; Peng Y; He S; Li R; Wang Z; Huang J; Lei X; Li G; Ma Q
Gastric Cancer; 2021 May; 24(3):642-654. PubMed ID: 33544270
[TBL] [Abstract][Full Text] [Related]
17. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma.
Mao J; Yang X; Lin J; Yang X; Wang D; Zhang L; Bai Y; Bian J; Long J; Xie F; Huang H; Sang X; Chen S; Zhao H
J Cancer; 2021; 12(5):1555-1562. PubMed ID: 33532001
[No Abstract] [Full Text] [Related]
18. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
20. Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report.
Rao J; Xia J; Yang W; Wu C; Sha B; Zheng Q; Cheng F; Lu L
Ann Transl Med; 2020 Dec; 8(23):1609. PubMed ID: 33437808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
